Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy
Open Access
- 6 September 2021
- journal article
- editorial
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 27, e934625-1-e934625-3
- https://doi.org/10.12659/msm.934625
Abstract
#934625 - Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy - Full ViewThis publication has 12 references indexed in Scilit:
- Editorial: Registries and Population Databases in Clinical Research and PracticeMedical Science Monitor, 2021
- Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control studyBMJ, 2021
- Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care WorkersJAMA, 2021
- Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021Eurosurveillance, 2021
- Hesitation and Refusal Factors in Individuals' Decision-Making Processes Regarding a Coronavirus Disease 2019 VaccinationFrontiers in Public Health, 2021
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination SettingThe New England Journal of Medicine, 2021
- Neutralizing Activity of BNT162b2-Elicited SerumThe New England Journal of Medicine, 2021
- First COVID-19 Vaccines Receiving the US FDA and EMA Emergency Use AuthorizationDiscoveries, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Vaccine hesitancy: the next challenge in the fight against COVID-19European Journal of Epidemiology, 2020